Brokerages Set Omnicell, Inc. (NASDAQ:OMCL) Price Target at $42.20

Omnicell, Inc. (NASDAQ:OMCL) has been assigned a consensus rating of “Hold” from the six ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $42.20.

OMCL has been the subject of a number of research analyst reports. Barclays assumed coverage on Omnicell in a report on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 price target for the company. Wells Fargo & Company cut their target price on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a research note on Friday, February 9th. Finally, Benchmark decreased their price target on shares of Omnicell from $42.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, February 9th.

Hedge Funds Weigh In On Omnicell

A number of hedge funds have recently made changes to their positions in OMCL. Covestor Ltd raised its holdings in shares of Omnicell by 65.6% in the 3rd quarter. Covestor Ltd now owns 1,355 shares of the company’s stock worth $61,000 after buying an additional 537 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Omnicell in the third quarter valued at $62,000. Neo Ivy Capital Management acquired a new position in Omnicell during the third quarter worth $78,000. Fifth Third Bancorp lifted its holdings in shares of Omnicell by 143.2% during the third quarter. Fifth Third Bancorp now owns 2,230 shares of the company’s stock valued at $100,000 after acquiring an additional 1,313 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Omnicell by 110.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,392 shares of the company’s stock valued at $153,000 after acquiring an additional 1,777 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Performance

Shares of OMCL opened at $27.13 on Tuesday. The company has a market capitalization of $1.25 billion, a PE ratio of -60.29 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.52 and a quick ratio of 2.22. Omnicell has a one year low of $25.69 and a one year high of $77.14. The company’s fifty day moving average price is $27.68 and its 200 day moving average price is $32.44.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. The business had revenue of $258.85 million for the quarter, compared to analyst estimates of $256.00 million. As a group, analysts expect that Omnicell will post 0.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.